GuidanceMarch 28, 2026
The biomarkers every cycle should monitor
A practical starting point for people using peptides, SARMs, or AAS without routine clinical supervision.
Insights
Articles, guidance, and research notes.
Evidence, commentary and updates from the SafePulse team and our clinical partners.
Featured
ResearchApril 18, 2026
Why the UK needs a harm-reduction Community Interest Company for performance enhancement
A look at why the gap between clinical practice and the communities using PEDs keeps widening — and the specific work SafePulse is doing to close it.
Recent
PolicyMarch 14, 2026
Speaking to Westminster on image enhancement
Notes from our session with the All-Party Parliamentary Group on Drug Policy Reform.
CommunityFebruary 22, 2026
What we learned from 500 user interviews
Trends in dosing, monitoring, and why so few users engage with primary care — summarised from our 2026 cohort.
ClinicalFebruary 8, 2026
How Chelsea Medical Practice fits into SafePulse
Inside the clinical partnership: referral pathways, bloods, and shared decision-making with users.